EP Patent

EP1214076B1 — Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Assigned to Bayer Pharma AG · Expires 2003-11-19 · 22y expired

What this patent protects

The present invention relates to a multiple-phase pharmaceutical preparation consisting of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, w…

USPTO Abstract

The present invention relates to a multiple-phase pharmaceutical preparation consisting of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage unit comprises a natural estrogen, such as estradiol in an amount of from 0.5 mg to 4 mg, and 2 to 4 mg of drospirenone, and wherein at least 70% of said drospirenone is dissolved from said dosage unit within 30 minutes, as determined by USP XXIII Paddle Method II using water at 37°C as the dissolution media and 50 rpm as the stirring rate.

Drugs covered by this patent

Patent Metadata

Patent number
EP1214076B1
Jurisdiction
EP
Classification
—
Expires
2003-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Pharma AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.